$DRMA News

Dermata Therapeutics (NASDAQ:DRMA) Q1 2026 Earnings: Narrowing Losses and Strategic Pivot to DTC Skincare

Dermata Therapeutics Q1 EPS $(0.48) Beats $(0.53) Estimate

Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025

Dermata Therapeutics Q4 EPS $(1.52) Beats $(1.54) Estimate

Dermata Shares Rise After USPTO Issues Patent Notice Of Allowance

Dermata Therapeutics shares are trading higher after the U.S. Patent and Trademark Office issued the company a notice of allowance for a U.S. patent titled "COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS."

Dermata Therapeutics shares are trading higher after the U.S. Patent and Trademark Office issued the company a notice of allowance for a U.S. patent titled "COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS."

Dermata Therapeutics shares are trading higher after the U.S. Patent and Trademark Office issued the company a notice of allowance for a U.S. patent titled "COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS"

UPDATE: Dermata Therapeutics Has Received A Notice Of Allowance For A U.S. Patent Titled "COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS"

Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing

Dermata Opens a New Chapter with the Release of Tome Skincare

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office

The Australian Patent Office Grants Dermata Therapeutics' Patent Application for Its Spongilla Technology Combination as a Method for Treating Acne

12 Health Care Stocks Moving In Tuesday's Intraday Session

Dermata Therapeutics shares are trading higher. Chairman Gerald Proehl reportedly purchased 612,745 shares at an average price of $2.04 per share.

Dermata Therapeutics Chairman Gerald Proehl Reported Purchase Of 612,745 Shares @Avg Price Of $2.04/Share In Form 4 Filing On Monday